title: Marked structural and functional heterogeneity in CXCR4: separation of HIV-1 and SDF-1alpha responses.
abstract: CXCR4, the chemotactic cell receptor for SDF-1alpha, is essential for immune trafficking and HIV infection. CXCR4 is remarkably heterogeneous and the purpose of this study was to better identify the isoforms expressed by cells and compare their structure and function. We found that cells express either a predominant isoform or multiple isoforms. These were best resolved on SDS-PAGE using sucrose-gradient-fractionated, triton-insoluble, membrane extracts. We hypothesized that glycosyl modification may underpin some of this heterogeneity and that cell isoform(s) differences may underscore CXCR4's multiple cell functions. A comparison of wild-type (WT) and dual N-linked glycosylation site, N11A/N176A, mutant CXCR4 expressed in 3T3 and HEK-293 cells served to implicate variabilities in glycosylation and oligomerization in almost half of the isoforms. Immunoprecipitation of CXCR4 revealed monomer and dimer non-glycosylated forms of 34 kDa and 68 kDa from the N11A/N176A mutant, compared with glycosylated 40 kDa and 47 kDa and 73 kDa and 80 kDa forms from WT. The functional specificity of isoform action was also implicated because, despite CEMT4 cells expressing high levels of CXCR4 and 11 different isoforms, a single 83 kDa form was found to bind gp120 for HIV-1 IIIB infection. Furthermore, comparative studies found that in contrast to SDF-1alpha-responsive Nalm-6 cells that expressed similar levels of a single isoform, CEMT4 cells did not show a Ca(++) flux or a chemotactic response to SDF-1alpha. Thus, CXCR4 can differ both structurally and functionally between cells, with HIV-1 infection and chemotaxis apparently mediated by different isoforms. This separation of structure and function has implications for understanding HIV-1 entry and SDF-1alpha responses and may indicate therapeutic possibilities.
authors.affiliation: HIV-Protein Interactions Laboratory, Centre for Virus Research, Westmead, NSW, Australia.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Sloane
authors.forename: Vic
authors.initials: V
authors.lastname: Raso
authors.forename: Dimiter S
authors.initials: DS
authors.lastname: Dimitrov
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Xiao
authors.forename: Shivashni
authors.initials: S
authors.lastname: Deo
authors.forename: Nick
authors.initials: N
authors.lastname: Muljadi
authors.forename: David
authors.initials: D
authors.lastname: Restuccia
authors.forename: Stuart
authors.initials: S
authors.lastname: Turville
authors.forename: Christine
authors.initials: C
authors.lastname: Kearney
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Broder
authors.forename: Hans
authors.initials: H
authors.lastname: Zoellner
authors.forename: Anthony L
authors.initials: AL
authors.lastname: Cunningham
authors.forename: Linda
authors.initials: L
authors.lastname: Bendall
authors.forename: Garry W
authors.initials: GW
authors.lastname: Lynch
mesh_terms: D000906:Antibodies / Q000276:immunology; D002118:Calcium / Q000378:metabolism; D054377:Chemokine CXCL12; D019743:Chemokines, CXC / Q000276:immunology* / Q000378:metabolism; D002633:Chemotaxis / Q000502:physiology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D015151:Immunoblotting; D019169:Jurkat Cells; D020033:Protein Isoforms / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D019718:Receptors, CXCR4 / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*
chemical_list: D000906:Antibodies; C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D019743:Chemokines, CXC; D020033:Protein Isoforms; D019718:Receptors, CXCR4; D002118:Calcium